CAS Key Laboratory of Soft Matter Chemistry, iChEM (Collaborative Innovation Center of Chemistry for Energy Materials), Department of Chemistry, University of Science and Technology of China, Hefei, Anhui 230026, P. R. China.
Institute of Cardiovascular Disease, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P. R. China.
Anal Chem. 2020 Oct 20;92(20):14113-14121. doi: 10.1021/acs.analchem.0c03131. Epub 2020 Oct 1.
Recently, nanoluminophores with the potential-resolved multicolor electrochemiluminescence (PRMCECL) property have emerged and shown promising applications in sensitive, selective, and accurate bioassays, bioimaging, and multicolor emitting devices. However, only limited PRMCECL nanoluminophores and their applications in ratiometric biosensors eliminating proportional errors have been reported. Herein, a novel PRMCECL nanoluminophore was synthesized by encapsulating CdS quantum dots (CdSQDs) into MOF-5 (CdSQDs@MOF-5). Using KSO as a coreactant, two electrochemiluminescence (ECL) peaks, ECL-1 centered at 685 nm and ECL-2 centered at 475 nm, were observed at -1.4 and -1.8 V, respectively. Related ECL mechanisms have been proposed. Based on the potential-resolved ECL signals, a label-free differential ECL immunosensor for the determination of cardiac troponin I (cTnI) was established by assembly of poly(diallyldimethylammonium chloride), CdSQDs@MOF-5, and cTnI antibody-functionalized silver nanoparticles on the surface of the fluorine-doped tin oxide electrode subsequently. In the presence of cTnI, cTnI was captured by the sensing interface, leading to an increase in ECL-1 and ECL-2 intensity. cTnI could be determined in the range of 0.01-1000 pg/mL with a detection limit of 5.01 fg/mL using the intensity difference between ECL-1 and ECL-2. This work provides a new family member of PRMCECL nanoluminophores. The proposed label-free differential ECL immunosensor provides a new strategy based on potential-resolved ECL signals, which could effectively eliminate the additive error and show better sensitivity, selectivity, and accuracy for the detection of cTnI than the single-signal strategy and ratiometric strategy.
最近,出现了具有潜力分辨多色电化学发光(PRMCECL)性能的纳米发光体,并在灵敏、选择性和准确的生物分析、生物成像和多色发射器件中显示出有前景的应用。然而,仅有有限数量的 PRMCECL 纳米发光体及其在消除比例误差的比率生物传感器中的应用被报道。在此,通过将 CdS 量子点(CdSQDs)封装到 MOF-5 中合成了一种新型的 PRMCECL 纳米发光体(CdSQDs@MOF-5)。使用 KSO 作为共反应物,在-1.4 和-1.8 V 下分别观察到两个电化学发光(ECL)峰,ECL-1 中心位于 685nm,ECL-2 中心位于 475nm。提出了相关的 ECL 机制。基于潜在分辨的 ECL 信号,通过将聚二烯丙基二甲基氯化铵、CdSQDs@MOF-5 和 cTnI 抗体功能化的银纳米粒子依次组装在氟掺杂氧化锡电极表面上,建立了用于测定心肌肌钙蛋白 I(cTnI)的无标记差分 ECL 免疫传感器。在存在 cTnI 的情况下,cTnI 被传感界面捕获,导致 ECL-1 和 ECL-2 强度增加。使用 ECL-1 和 ECL-2 强度之间的差异,可以在 0.01-1000pg/mL 的范围内检测到 cTnI,检测限为 5.01fg/mL。这项工作提供了一种新的 PRMCECL 纳米发光体家族成员。所提出的无标记差分 ECL 免疫传感器提供了一种基于潜在分辨 ECL 信号的新策略,该策略可以有效地消除加性误差,并比单信号策略和比率策略更灵敏、选择性和准确地检测 cTnI。